The approval of ICIs, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, has led to durable clinical responses and long-term remissions in various cancers, including CRC (Topalian et al., 2012). Here, CD274 is linked to colorectal carcinoma.